Search results
Results from the Health.Zone Content Network
Target. Immunisation of the public in the United Kingdom against COVID-19. Participants. 53,710,109 have received one vaccine dose. 50,483,527 have received two vaccine doses. 40,196,024 have received three vaccine doses, 6,200,537 have received a fourth dose [1] Outcome. 92.9% of UK population 12+ have received one vaccine dose.
A vaccination schedule is a series of vaccinations, including the timing of all doses, which may be either recommended or compulsory, depending on the country of residence. A vaccine is an antigenic preparation used to produce active immunity to a disease , in order to prevent or reduce the effects of infection by any natural or "wild" pathogen ...
The Joint Committee on Vaccination and Immunisation ( JCVI) is an independent expert advisory committee that advises United Kingdom health departments on immunisation, making recommendations concerning vaccination schedules and vaccine safety. It has a statutory role in England and Wales, and health departments in Scotland and Northern Ireland ...
You don’t have to wait between getting the COVID-19 vaccine and others, such as the shingles or flu vaccines. Your doctor can answer any questions or concerns you may have about the timing of ...
A 2022 study of the Pfizer vaccine and the Omicron variant found that vaccine effectiveness was 67.2 percent in the 2 to 4 weeks after a booster, but declined to 45.7 percent after 10 or more weeks.
The bivalent vaccine used in the UK targets the BA.1 Omicron variant, while US vaccines target the BA.4 and BA.5 Omicron variants. These variants are all related to the currently circulating ...
Immunisation against infectious disease is popularly known as The Green Book, to provide information on the UK's vaccination schedule and vaccines for vaccine preventable infectious diseases. [1] [2] It is a guide for health professionals and health departments that give vaccines in the UK. [2] Updates are added by its clinical editors through ...
The meningococcal conjugate vaccine or MCV4 was approved in 2005. It uses antigens taken from the polysaccharide capsule and then bound to a separate protein that targets the body's immune cells ...